Abstract:Abstract Introduction: Amplification of receptor tyrosine-protein kinase erbB-2 gene (ERBB2), also known as HER2, can serve as an effective biomarker for either dual targeted therapy with trastuzumab plus lapatinib or pertuzumab plus trastuzumab in treating refractory metastatic colorectal cancer (CRC) as shown in HERACLES and MyPathway clinical trials. Next-generation sequencing (NGS) based comprehensive genomic profiling (CGP) has increasingly proven to be a valuable analysis and detection method that can make a significant impact on cancer treatment decisions. Experimental Procedure: Comprehensive genomic profiling was performed with a 450-gene next-generation sequencing (NGS) panel on both FFPE tumor and matched blood samples from a cohort of 123 Chinese colorectal cancer patients comprising 76 males and 47 females (median age was 60). All classes of genomic alterations including single-nucleotide variations, short and long insertions and deletions, copy number variations, and gene fusions were detected. Tumor mutational burden (TMB) and microsatellite instability (MSI) status were also determined by algorithms-based NGS data. Results: The most common altered genes in the 123 CRC Chinese patients were TP53 (71%), APC (70%) and KRAS (50%). 19 pts were detected by NGS as MSI-high with a median TMB value of 119 muts/Mb, which was significantly higher than in the MSS subgroup (104 pts) with a median TMB value of 10 muts/Mb (p-value was 1.5E-08). In total, 9% of the CRC pts harbored ERBB2 amplifications (11/123) by NGS panel, and it was much higher than 3-4% in Western populations. Interestingly, all 11 ERBB2 amplified cases were presented exclusively in the MSS subgroup (11/104, 11%), and were all BRAF wild-type. Five out of the 11 cases were KRAS wild-type. In addition, 9 confirmed somatic ERBB2 point mutations in the COSMIC database were detected in 7 CRC pts (7/123, 6%), including T166M, S280F, A324T, R678Q, V812I, L725S, V842I and H848Y. Four pts were MSI-high. Conclusion: CGP reveals significantly higher prevalence of both amplifications and point mutations of ERBB2/HER2 in Chinese CRC patients, compared with Western population. It may identify a subgroup of CRC patients potentially benefiting from specific targeted therapies including anti-HER2 therapies. Moreover, the highly exclusive presence of ERBB2 amplifications with MSS status could provide these patients with broader precision treatment opportunity. Citation Format: Sen Zhang, Yun Guo, Jun Jia, Weibin Shu, Hui Li, Yu Wang, Wei Zhao, Zusen Wang, Xueqing Yao, Tao Xiang, Yong Li, Ting Deng, Weifeng Wang, Kai Wang. High incidence of ERBB2 amplification associated with microsatellite stable status in Chinese colorectal cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4333.

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2

Abstract 4333: High Incidence of ERBB2 Amplification Associated with Microsatellite Stable Status in Chinese Colorectal Cancer Patients

Abstract 5536: Landscape and Analysis of ERBB2 Amplification and Short Variant Mutations in Large-Scale Chinese Patients with Colorectal Cancer

Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype.

Molecular and Clinicopathological Characteristics of ERBB2 Gene Fusions in 32,131 Chinese Patients with Solid Tumors.

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.

Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

HER2 Overexpression and Amplification in Patients with Colorectal Cancer: a Large-Scale Retrospective Study in Chinese Population.

Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer.

Clinic-pathological characteristics of MMR protein, KRAS-NRAS-BRAF gene mutation, HER-2 and PD-L1 status in 3822 Chinese colorectal cancer patients

Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population

Gene Mutation Profiling in Chinese Colorectal Cancer Patients and Its Association with Clinicopathological Characteristics and Prognosis

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Clinical-Molecular Characteristics and Post-Translational Modifications of Colorectal Cancer in North China: Implications for Future Targeted Therapies

Whole Exome Sequencing Of Ulcerative Colitis-Associated Colorectal Cancer Based On Novel Somatic Mutations Identified In Chinese Patients

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer

ERBB2 Mutation Profiling with Next-Generation Sequencing (NGS) in Solid Tumors.